Drug Profile
Codrituzumab - Chugai Pharmaceutical/Roche
Alternative Names: GC-33; RG-7686; RO-5137382Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Perseus Proteomics
- Developer Chugai Pharmaceutical; Roche
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Glypican 3 inhibitors; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Liver cancer
- Phase I Solid tumours
Most Recent Events
- 23 May 2022 Codrituzumab is still in phase I trials for Liver cancer (Combination therapy, Late-stage disease, Metastatic disease) in Japan and Taiwan (IV) (JapicCTI-163325)
- 27 Apr 2022 Phase II development is ongoing in Liver cancer (Roche pipeline, April 2022 )
- 09 Jun 2021 Phase-I clinical trials in Solid tumours (In children, In adults, In adolescents, In infants, Second-line therapy or greater) in USA (IV)